[go: up one dir, main page]

US20020086856A1 - Medicament for preventing and/or treating a mammary carcinoma, containing a steroidal aromatase inhibitor - Google Patents

Medicament for preventing and/or treating a mammary carcinoma, containing a steroidal aromatase inhibitor Download PDF

Info

Publication number
US20020086856A1
US20020086856A1 US10/016,107 US1610701A US2002086856A1 US 20020086856 A1 US20020086856 A1 US 20020086856A1 US 1610701 A US1610701 A US 1610701A US 2002086856 A1 US2002086856 A1 US 2002086856A1
Authority
US
United States
Prior art keywords
medicament
use according
formestane
steroidal aromatase
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/016,107
Inventor
Alfred Schmidt
Heinrich Wieland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SAVETHERAPEUTICS AG
Global Clean Energy Holdings Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP98104949A external-priority patent/EP0943333A1/en
Application filed by Individual filed Critical Individual
Priority to US10/016,107 priority Critical patent/US20020086856A1/en
Publication of US20020086856A1 publication Critical patent/US20020086856A1/en
Priority to US10/227,523 priority patent/US20030092693A1/en
Assigned to SAVETHERAPEUTICS, AG reassignment SAVETHERAPEUTICS, AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: WIELAND, DR. HEINRICH
Assigned to MEDICAL DISCOVERIES, INC. reassignment MEDICAL DISCOVERIES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SAVETHERAPEUTICS, A.G.
Priority to US11/315,003 priority patent/US8343948B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone

Definitions

  • the invention relates to a medicament for the prophylaxis (primary and secondary prophylaxis) and/or treatment of breast cancer.
  • oestrogen and/or progesterone receptors are found in the cytoplasm.
  • Breast cancers of this type need oestrogen for the proliferation of their cells.
  • Oestrogens act by binding to specific intracellular (cytoplasmic) receptors of oestrogen-sensitive cells, into which they are passively introduced by diffusion from the plasma. The binding changes the configuration of the receptor protein.
  • the receptor-hormone complex controls both the transcription and the expression of specific genes; the synthesis of growth-promoting and/or growth-inhibiting factors caused thereby finally has an effect on cell growth.
  • Tamoxifen occupies the oestrogen receptors located in the cytoplasm of the cancer cells and thus causes competitive displacement of oestrogens.
  • the complex formed from tamoxifen and the oestrogen receptor prevents the transcription and the expression of genes promoting cell growth, which otherwise is caused by a complex formed from oestrogens and the receptor.
  • tamoxifen also has a growth-inhibiting and, under certain circumstances, even cytostatic effect on cell lines which have no oestrogen receptors. Tamoxifen inhibits protein kinase C and blocks the activation of calmodulin. It increases the activity of the killer cells and inhibits suppressor T lymphocytes.
  • tamoxifen can act on cancer cells as well as oestrogens in a manner which is not known in greater detail and promotes their growth. Relatively long-lasting tamoxifen treatment can therefore lead, under certain circumstances, to tumour growth. It moreover leads to a risk which is increased by a factor of 3 to 5 of suffering from cancer of the endometrium. In view of the clinical benefits of tamoxifen therapy, this risk is accepted in breast cancer patients.
  • Aromatase is a complex enzyme system which catalyses the conversion of adrenal androgens to oestrone and oestradiol.
  • Formestane is a derivative of the physiological steroid hormone androstenedione and binds competitively to other substrates of aromatase. During catalysis, it damages the enzyme molecule irreversibly. Systemic treatment with formestane is likewise used as an antioestrogenic breast cancer therapy.
  • the invention is based on the object of creating a medicament of the type mentioned at the outset, which is suitable for treatment, and in particular also prophylaxis, of breast cancer.
  • the invention achieves this object by formulating a steroidal aromatase inhibitor to give a medicament intended for topical application.
  • the use of antigestagens as an additional constituent of the medicament is excluded in the context of the invention.
  • steroidal aromatase inhibitors are used as substances inhibiting the formation of oestrogens. These inhibit oestrogen biosynthesis from the androgenic precursors, for example the enzymatic conversion of androstenedione to oestrone or of testosterone to oestradiol. Since the two synthesis steps mentioned are mediated by the enzyme system of the aromatase (converting enzyme), aromatase inhibitors are used in the context of the invention. Preferred inhibitors are those which bind to the aromatase and irreversibly damage this. After topical application, they penetrate through the skin and concentrate in the fatty tissue.
  • the medicament according to the invention is intended for topical application.
  • the medicament is applied locally to the skin, the preferably strongly lipophilic active compound is transdermally absorbed and thus brought locally to the intended site of act-on.
  • the active compound concentrates in the periductal fatty tissue.
  • the fatty matter of the treated breast is markedly reduced. This reduction decreases the quantity of oestrogen-forming cells having oestrogen-forming competence.
  • the lipophilicity and hydrophobicity of the active compound has the result that the active compound is exclusively concentrated locally in the fatty tissue and can display no systemic action.
  • Oestrogens are understood as meaning all female sex hormones having an action comparable, for example, to that of oestrone and oestradiol.
  • aromatase inhibitors known from the prior art such as formestane
  • it is intended to transport these to the site of action via the blood circulation.
  • High serum concentrations of the aromatase inhibitor are aimed at, which, in addition to the desired action in the tumour, can lead to systemic side effects.
  • side effects are accepted in acute therapy in view of the success desired.
  • this does not come into consideration in the case of a preventive treatment against a still unexisting or clearly detected disease.
  • the invention is intended to apply the medicament topically immediately on or in the vicinity of the intended site of action. Unlike the prior art, no transport via the blood circulation to the intended site of action is aimed at. According to the invention, the result achieved is an adequate local active compound level in the tissue at risk (in prophylaxis) or in the diseased tissue (in therapy) without a noticeable absorption of the active compound taking place in the blood circulation.
  • the crux of the invention is thus not only in the topical application per se, but in the local topical application in such a way that the active compound concentrates immediately in the tissue at risk and/or diseased tissue, and not indirectly via the blood circulation.
  • the medicament according to the invention can be applied topically to the intended site of action in such an amount that a noticeable absorption in the blood circulation. additionally takes place and a serum level thus builds up which also transports the active compound to metastases. In this use too, a local absorption on or in the vicinity of the intended site of action also primarily takes place.
  • the medicament can be used for the treatment of breast cancer. After surgical primary care and, if appropriate, appropriate adjuvant therapy, this treatment can replace and/or supplement the hitherto customary systemic antioestrogenic therapy.
  • An important advantage of the invention is the possibility of also using the medicament for breast cancer prophylaxis.
  • a particularly advantageous possibility of employment is so-called secondary prophylaxis.
  • female patients in whom a breast cancer is already present there is a particularly high risk of a further carcinoma in the contralateral breast.
  • the contralateral breast can then be treated prophylactically with the medicament according to the invention.
  • a secondary prophylactic treatment of the diseased breast to avoid local recurrences is likewise possible.
  • primary prophylaxis can be performed.
  • the selection criteria which can be used for such a high-risk group are, for example, the facts that at least one female relative of first degree on the mother's side is or has been suffering from breast cancer on one side before the 45th year of life or bilaterally, or that on the mothers side at least one female relative of first degree and an additional female relative are or have been suffering from breast cancer.
  • the indication for primary prophylaxis can be made relatively generously already in the presence of tissue having a comparatively low or average risk (for example histological finding Prechtel II or III). Prophylaxis can be started even if the conventional early diagnosis (palpation finding) is still negative, since this customary early diagnosis is inadequate and as a rule only detects a breast cancer when a systemic disease which is barely still curable is already present.
  • the medicament according to the invention is preferably applied locally and topically over a relatively long period of time (if needed up to lifelong) and application is carried out, for example, once or twice per day.
  • the active substances are selected from the group consisting of the (preferably lipid-soluble) steroidal aromatase inhibitors. On topical application, these lipid-soluble substances penetrate into the fatty tissue and locally prevent the de novo formation of oestrogens from the oestrogen precursors.
  • steroidal aromatase inhibitors such as 4-hydroxyandrost-4-ene-3,17-dione (formestane), 6-methyleneandrostra-1,4-diene-3,17-dione (exemestane), 10-(2-propynyl)estr-4-ene-3,17-dione (MDL 18962) and 7- ⁇ -substituted androstenedione derivatives can be used.
  • the active compound is brought to the intended site of application by local application.
  • the invention achieves a reduction of the aromatase activity in the fatty tissue of the breast, i.e. exactly in the position in which a tumour can be formed or grow.
  • the fatty matter of the breast On relatively long-term use, the fatty matter of the breast and thus the amount of possible risk tissue is reduced. Since breast cancers are frequently formed in upper breast quadrants of increased aromatase activity, particularly effective prophylaxis is possible there according to the invention.
  • aromatase inhibitors can be employed prophylactically or therapeutically even against those tumours of the breast which are themselves able to produce oestrogen or autocrine/paracrine stimulation.
  • a lowering of the oestrogen concentration in the plasma barely has an effect on such tumours, but the reduction of the intratumoral aromatase concentration to be achieved according to the invention can affect such tumours on account of the use of cell-permeable inhibitors.
  • the active compounds administered according to the invention remain localized in the fatty tissue of the breast and display their intended action there on account of their lipid solubility, the side effects induced by systemic application are eliminated. This reduction or exclusion of side effects allows significantly wider prophylactic use.
  • the medicament according to the invention can be applied by patients themselves and frequent visits to the doctor for this purpose are not necessary.
  • a medicament formulated according to the invention preferably contains formestane.
  • Formestane derivatives such as, for example, acetylated formestane (for example 4-O-acetylandrost-4-ene-3,17-dione) are likewise preferably utilizable.
  • the acetylation of the formestane increases its hydrophilicity and thus skin penetration significantly. Since the acetyl group is hydrolysed under the conditions prevailing in the subcutaneous region after passage through the skin, the actual active compound formestane is formed again in situ.
  • acetylated formestane a precursor of the actual active compound penetrating better through the skin is thus applied and the inventors have recognized that the actual active compound is formed in situ subcutaneously from this precursor.
  • the active compounds used according to the invention are lipid-soluble and highly suitable for topical application.
  • the concentration in the fatty tissue of the breast avoids systemic side effects.
  • substances known in the prior art which promote this can be added to the medicament according to the invention, for example hyaluronidases or DMSO (dimethyl sulphoxide).
  • the medicament is preferably formulated as an ointment, cream, gel, emulsion or lotion.
  • Formulation as a powder or oil is also conceivable.
  • Formulation bases are familiar to the person skilled in the art from the cosmetic and pharmaceutical industry and do not need to be explained here in greater detail.
  • vegetable oils and fats such as almond oil, peanut oil, olive oil, peach kernel oil, castor oil, plant extracts, ethereal oils; furthermore vegetable waxes and synthetic and animal oils, fats or waxes; lecithin, lanolin alcohols, carotene, fragrances, mono- or polyhydric alcohols, urea, preservatives and colourants etc.
  • Formulation as an oil-in-water or water-in-oil emulsion is preferred.
  • the active compound content of the medicament (the content of substances inhibiting the formation of oestrogens) can be between 0.0001 and 20% by weight, preferably 0.6 and 10% by weight, further preferably 1 and 5% by weight.
  • a customary range is 0.6 to 2% by weight.
  • substances when admixed to promote skin penetration absorption, their content, when using hyaluronidases, can be, for example, between 0.01 and 1% by weight, preferably 0.05 and 0.2% by weight; when using DMSO between 1 and 25% by weight, preferably 5 and 10% by weight.
  • FIG. 1 shows the cytological result of a fatty cell aspirate before use of the medicament according to the invention
  • FIG. 2 shows the corresponding result after daily use over the course of 3 months.
  • a gel was prepared from the following constituents: Ethanol 90% 7.0 g Carbopol 934 P 7.0 g Triethanolamine 2 g Polysorbate 80 5.0 g Glycerol 3.0 g Formestane 0.75 g purified water to 100 g
  • a cream was prepared from the following constituents: Propylene glycol 25.0 g Isopropyl myristate 6.0 g Sorbitan monostearate 1.0 g Polysorbate 80 2.0 g Cetylstearyl alcohol 6.0 g Stearyl alcohol 2.0 g Glycerol monostearate 1.0 g Hyaluronic acid 0.1 g Formestane 1.5 g purified water to 100 g
  • a cream was prepared from the following constituents.
  • the constituents are indicated in this example by their INCI names.
  • a cream was prepared from the following constituents, which are indicated by their INCI names.
  • a fine needle aspirate of the fatty tissue (0.6 mm puncture needle, fixation in absolute ethanol, staining: May-Grünwald-Giemsa) was withdrawn (FIG. 1). Distended fat cells and eccentric cell nuclei as a result of a high oestrogen influx are detected.
  • FIG. 2 shows the fatty tissue aspirate after this use.
  • a reduction in volume of the fatty tissue (“shrivelled” fat cells in a regular arrangement) and an increase in connective tissue is detected due to the aromatase inhibition.
  • the results showed a reduction of the tissue at risk by about 50% and a distinct firming of connective tissue and skin.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A method of prophylaxis and/or treatment of mastocarcinoma (i.e., mammary carcinoma) involves the topical application of a therapeutically or prophylactically effective amount of a steroidal aromatase inhibitor locally, and not systemically, to an area of a patient in need of treatment. This local application avoids the side effects associated with systemic use of steroidal aromatase inhibitors.

Description

  • The invention relates to a medicament for the prophylaxis (primary and secondary prophylaxis) and/or treatment of breast cancer. [0001]
  • Breast cancer is the most frequent malignant disease in women. In Germany, breast cancer makes up about 20% of all cases of cancer in women; the incidence at present is about 30,000 new cases of disease per annum. The adjuvant cancer therapy used today does lead to an increase in the survival rate; breast cancer screening and early surgical treatment can also lower the mortality by over 30%. However, since the number of new cases of disease is continuously increasing, the death rate measured over the total population remains the same or increases. Until now, it has barely been possible to affect the number of new cases, as too little is known about triggering factors. [0002]
  • In approximately half of all breast cancers, oestrogen and/or progesterone receptors are found in the cytoplasm. Breast cancers of this type need oestrogen for the proliferation of their cells. Oestrogens act by binding to specific intracellular (cytoplasmic) receptors of oestrogen-sensitive cells, into which they are passively introduced by diffusion from the plasma. The binding changes the configuration of the receptor protein. The receptor-hormone complex controls both the transcription and the expression of specific genes; the synthesis of growth-promoting and/or growth-inhibiting factors caused thereby finally has an effect on cell growth. [0003]
  • By withdrawal of oestrogens, regression of oestrogen-dependent tumours can be achieved. In premenopausal women, the ovaries are the main source of oestrogens. Their surgical removal has therefore been carried out since 1896 with breast cancer in the advanced stage (metastasis formation) as a so-called surgical hormone therapy. [0004]
  • In post-menopausal women, the conversion of adrenal androgens, especially androstenedione and testosterone, to oestrone and oestradiol is the main source of oestrogen. The conversion to oestrogens takes place in the muscle and fatty tissue. [0005]
  • In clinical practice, for over twenty years both early and advanced stages of breast cancer have been treated with tamoxifen or its derivatives (in particular tamoxifen citrate). Tamoxifen occupies the oestrogen receptors located in the cytoplasm of the cancer cells and thus causes competitive displacement of oestrogens. The complex formed from tamoxifen and the oestrogen receptor prevents the transcription and the expression of genes promoting cell growth, which otherwise is caused by a complex formed from oestrogens and the receptor. [0006]
  • In in-vitro experiments, it has been demonstrated that tamoxifen also has a growth-inhibiting and, under certain circumstances, even cytostatic effect on cell lines which have no oestrogen receptors. Tamoxifen inhibits protein kinase C and blocks the activation of calmodulin. It increases the activity of the killer cells and inhibits suppressor T lymphocytes. [0007]
  • In particular after relatively long treatment, tamoxifen can act on cancer cells as well as oestrogens in a manner which is not known in greater detail and promotes their growth. Relatively long-lasting tamoxifen treatment can therefore lead, under certain circumstances, to tumour growth. It moreover leads to a risk which is increased by a factor of 3 to 5 of suffering from cancer of the endometrium. In view of the clinical benefits of tamoxifen therapy, this risk is accepted in breast cancer patients. [0008]
  • The systemic treatment of breast cancers with aromatase inhibitors, in particular 4-hydroxyandrost-4-ene-3,17-dione (INN formestane) is further Known. Aromatase is a complex enzyme system which catalyses the conversion of adrenal androgens to oestrone and oestradiol. [0009]
  • Formestane is a derivative of the physiological steroid hormone androstenedione and binds competitively to other substrates of aromatase. During catalysis, it damages the enzyme molecule irreversibly. Systemic treatment with formestane is likewise used as an antioestrogenic breast cancer therapy. [0010]
  • The invention is based on the object of creating a medicament of the type mentioned at the outset, which is suitable for treatment, and in particular also prophylaxis, of breast cancer. [0011]
  • The invention achieves this object by formulating a steroidal aromatase inhibitor to give a medicament intended for topical application. The use of antigestagens as an additional constituent of the medicament is excluded in the context of the invention. [0012]
  • Some terms used in the context of the invention will first be explained. [0013]
  • According to the invention, steroidal aromatase inhibitors are used as substances inhibiting the formation of oestrogens. These inhibit oestrogen biosynthesis from the androgenic precursors, for example the enzymatic conversion of androstenedione to oestrone or of testosterone to oestradiol. Since the two synthesis steps mentioned are mediated by the enzyme system of the aromatase (converting enzyme), aromatase inhibitors are used in the context of the invention. Preferred inhibitors are those which bind to the aromatase and irreversibly damage this. After topical application, they penetrate through the skin and concentrate in the fatty tissue. [0014]
  • The medicament according to the invention is intended for topical application. The medicament is applied locally to the skin, the preferably strongly lipophilic active compound is transdermally absorbed and thus brought locally to the intended site of act-on. The active compound concentrates in the periductal fatty tissue. In a long-term treatment, the fatty matter of the treated breast is markedly reduced. This reduction decreases the quantity of oestrogen-forming cells having oestrogen-forming competence. The lipophilicity and hydrophobicity of the active compound has the result that the active compound is exclusively concentrated locally in the fatty tissue and can display no systemic action. Oestrogens are understood as meaning all female sex hormones having an action comparable, for example, to that of oestrone and oestradiol. [0015]
  • In the use of aromatase inhibitors known from the prior art, such as formestane, it is intended to transport these to the site of action via the blood circulation. High serum concentrations of the aromatase inhibitor are aimed at, which, in addition to the desired action in the tumour, can lead to systemic side effects. In view of the severity of the illness, such side effects are accepted in acute therapy in view of the success desired. However, this does not come into consideration in the case of a preventive treatment against a still unexisting or clearly detected disease. [0016]
  • According to the invention, however, it is intended to apply the medicament topically immediately on or in the vicinity of the intended site of action. Unlike the prior art, no transport via the blood circulation to the intended site of action is aimed at. According to the invention, the result achieved is an adequate local active compound level in the tissue at risk (in prophylaxis) or in the diseased tissue (in therapy) without a noticeable absorption of the active compound taking place in the blood circulation. The crux of the invention is thus not only in the topical application per se, but in the local topical application in such a way that the active compound concentrates immediately in the tissue at risk and/or diseased tissue, and not indirectly via the blood circulation. [0017]
  • If metastasizing carcinomas are also to be treated and/or prophylaxis is to be carried out against these, the medicament according to the invention can be applied topically to the intended site of action in such an amount that a noticeable absorption in the blood circulation. additionally takes place and a serum level thus builds up which also transports the active compound to metastases. In this use too, a local absorption on or in the vicinity of the intended site of action also primarily takes place. [0018]
  • The medicament can be used for the treatment of breast cancer. After surgical primary care and, if appropriate, appropriate adjuvant therapy, this treatment can replace and/or supplement the hitherto customary systemic antioestrogenic therapy. [0019]
  • An important advantage of the invention is the possibility of also using the medicament for breast cancer prophylaxis. A particularly advantageous possibility of employment is so-called secondary prophylaxis. In female patients in whom a breast cancer is already present, there is a particularly high risk of a further carcinoma in the contralateral breast. The contralateral breast can then be treated prophylactically with the medicament according to the invention. A secondary prophylactic treatment of the diseased breast to avoid local recurrences is likewise possible. [0020]
  • In the case of so-called high-risk women, primary prophylaxis can be performed. The selection criteria which can be used for such a high-risk group are, for example, the facts that at least one female relative of first degree on the mother's side is or has been suffering from breast cancer on one side before the 45th year of life or bilaterally, or that on the mothers side at least one female relative of first degree and an additional female relative are or have been suffering from breast cancer. Since the local application according to the invention virtually completely avoids possible systemic side effects of the active compound on account of its hydrophobicity, the indication for primary prophylaxis can be made relatively generously already in the presence of tissue having a comparatively low or average risk (for example histological finding Prechtel II or III). Prophylaxis can be started even if the conventional early diagnosis (palpation finding) is still negative, since this customary early diagnosis is inadequate and as a rule only detects a breast cancer when a systemic disease which is barely still curable is already present. [0021]
  • The medicament according to the invention is preferably applied locally and topically over a relatively long period of time (if needed up to lifelong) and application is carried out, for example, once or twice per day. [0022]
  • The active substances are selected from the group consisting of the (preferably lipid-soluble) steroidal aromatase inhibitors. On topical application, these lipid-soluble substances penetrate into the fatty tissue and locally prevent the de novo formation of oestrogens from the oestrogen precursors. [0023]
  • For example, steroidal aromatase inhibitors such as 4-hydroxyandrost-4-ene-3,17-dione (formestane), 6-methyleneandrostra-1,4-diene-3,17-dione (exemestane), 10-(2-propynyl)estr-4-ene-3,17-dione (MDL 18962) and 7-α-substituted androstenedione derivatives can be used. [0024]
  • The names mentioned in brackets are the INNs (International nonproprietary names). For the terminology and structure of the substances mentioned, reference is likewise made to the “Rote Liste” and Rompp's chemical encylopaedia. [0025]
  • Until now, the substances mentioned have only been used for the systemic therapy of breast cancer. According to the invention, however, the active compound is brought to the intended site of application by local application. When using aromatase inhibitors, the invention achieves a reduction of the aromatase activity in the fatty tissue of the breast, i.e. exactly in the position in which a tumour can be formed or grow. On relatively long-term use, the fatty matter of the breast and thus the amount of possible risk tissue is reduced. Since breast cancers are frequently formed in upper breast quadrants of increased aromatase activity, particularly effective prophylaxis is possible there according to the invention. [0026]
  • The use according to the invention of aromatase inhibitors can be employed prophylactically or therapeutically even against those tumours of the breast which are themselves able to produce oestrogen or autocrine/paracrine stimulation. A lowering of the oestrogen concentration in the plasma barely has an effect on such tumours, but the reduction of the intratumoral aromatase concentration to be achieved according to the invention can affect such tumours on account of the use of cell-permeable inhibitors. Since the active compounds administered according to the invention remain localized in the fatty tissue of the breast and display their intended action there on account of their lipid solubility, the side effects induced by systemic application are eliminated. This reduction or exclusion of side effects allows significantly wider prophylactic use. The medicament according to the invention can be applied by patients themselves and frequent visits to the doctor for this purpose are not necessary. [0027]
  • A medicament formulated according to the invention preferably contains formestane. [0028]
  • Formestane derivatives such as, for example, acetylated formestane (for example 4-O-acetylandrost-4-ene-3,17-dione) are likewise preferably utilizable. The acetylation of the formestane increases its hydrophilicity and thus skin penetration significantly. Since the acetyl group is hydrolysed under the conditions prevailing in the subcutaneous region after passage through the skin, the actual active compound formestane is formed again in situ. When using such an acetylated formestane, a precursor of the actual active compound penetrating better through the skin is thus applied and the inventors have recognized that the actual active compound is formed in situ subcutaneously from this precursor. [0029]
  • As a rule, the active compounds used according to the invention are lipid-soluble and highly suitable for topical application. As already described above, the concentration in the fatty tissue of the breast avoids systemic side effects. To improve the skin penetration, substances known in the prior art which promote this can be added to the medicament according to the invention, for example hyaluronidases or DMSO (dimethyl sulphoxide). [0030]
  • The medicament is preferably formulated as an ointment, cream, gel, emulsion or lotion. Formulation as a powder or oil is also conceivable. Formulation bases are familiar to the person skilled in the art from the cosmetic and pharmaceutical industry and do not need to be explained here in greater detail. For example, vegetable oils and fats such as almond oil, peanut oil, olive oil, peach kernel oil, castor oil, plant extracts, ethereal oils; furthermore vegetable waxes and synthetic and animal oils, fats or waxes; lecithin, lanolin alcohols, carotene, fragrances, mono- or polyhydric alcohols, urea, preservatives and colourants etc. can be used. Formulation as an oil-in-water or water-in-oil emulsion is preferred. [0031]
  • The active compound content of the medicament (the content of substances inhibiting the formation of oestrogens) can be between 0.0001 and 20% by weight, preferably 0.6 and 10% by weight, further preferably 1 and 5% by weight. A customary range is 0.6 to 2% by weight. [0032]
  • If substances are admixed to promote skin penetration absorption, their content, when using hyaluronidases, can be, for example, between 0.01 and 1% by weight, preferably 0.05 and 0.2% by weight; when using DMSO between 1 and 25% by weight, preferably 5 and 10% by weight.[0033]
  • Embodiments of the invention are described below. In the drawing: [0034]
  • FIG. 1 shows the cytological result of a fatty cell aspirate before use of the medicament according to the invention, [0035]
  • FIG. 2 shows the corresponding result after daily use over the course of 3 months.[0036]
    • EXAMPLE 1
  • The following constituents were mixed to give a cream: [0037]
    Urea 10 g
    Titaniun oxide 15 g
    Crude petroleum jelly 20 g
    Isopropyl palmitate 10 g
    Hardened peanut oil 10 g
    Tween 80 5 g
    Formestane 1 g
    made up with purified water to 100 g
    • EXAMPLE 2
  • A gel was prepared from the following constituents: [0038]
    Ethanol 90% 7.0 g
    Carbopol 934 P 7.0 g
    Triethanolamine 2 g
    Polysorbate 80 5.0 g
    Glycerol 3.0 g
    Formestane 0.75 g
    purified water to 100 g
    • EXAMPLE 3
  • A cream was prepared from the following constituents: [0039]
    Propylene glycol 25.0 g
    Isopropyl myristate 6.0 g
    Sorbitan monostearate 1.0 g
    Polysorbate 80 2.0 g
    Cetylstearyl alcohol 6.0 g
    Stearyl alcohol 2.0 g
    Glycerol monostearate 1.0 g
    Hyaluronic acid 0.1 g
    Formestane 1.5 g
    purified water to 100 g
    • EXAMPLE 4
  • A cream was prepared from the following constituents. The constituents are indicated in this example by their INCI names. [0040]
    INCI
    Ceteareth-25 3.0 g
    PEG-4-polyglyceryl 2-stearate 2.0 g
    Cetearyl alcohol 4.9 g
    Petrolatum 10.0 g
    Paraffinum perliquidum 3.0 g
    Sodium carbomer 400 0.14 g
    Lactic acid 0.02 g
    Paraffinum perliquidum 2.0 g
    Phenoxyethanol, dehydroacetic acid, 0.4 g
    benzoic acid
    Perfume 0.08 g
    Formestane 1.5 g
    made up with water to 100 g
  • The mixture of phenoxyethanol, dehydroacetic acid and benzoic acid mentioned in the formulation is obtainable from Schülke & Mayr under the name Euxyl[0041] R K702.
    • EXAMPLE 5
  • A cream was prepared from the following constituents, which are indicated by their INCI names. [0042]
    INCI
    Ceteareth-25 3.0 g
    PEG-4-polyglyceryl 2-stearate 2.0 g
    Cetearyl alcohol 4.9 g
    Petrolatum 10.0 g
    Paraffinum perliquidum 3.0 g
    Sodium carbomer 400 0.14 g
    Lactic acid 0.02 g
    Paraffinum perliquidum 2.0 g
    Phenoxyethanol, dehydroacetic acid, 0.4 g
    benzoic acid
    Perfume 0.08 g
    4-acetylandrost-4-ene-3,17-dione 1.5 g
    (acetylated formestane)
    made up with water to 100 g
    • EXAMPLE 6
  • A clinical test of the recipe according to Example 1 was carried out. The findings of oversize breasts and medium-grade mastopathy were present in the 25-year-old volunteer. [0043]
  • A fine needle aspirate of the fatty tissue (0.6 mm puncture needle, fixation in absolute ethanol, staining: May-Grünwald-Giemsa) was withdrawn (FIG. 1). Distended fat cells and eccentric cell nuclei as a result of a high oestrogen influx are detected. [0044]
  • The volunteer then applied the cream according to Example 1 twice daily over a period of 3 months. FIG. 2 shows the fatty tissue aspirate after this use. A reduction in volume of the fatty tissue (“shrivelled” fat cells in a regular arrangement) and an increase in connective tissue is detected due to the aromatase inhibition. The results showed a reduction of the tissue at risk by about 50% and a distinct firming of connective tissue and skin. [0045]

Claims (7)

1. Use of a steroidal aromatase inhibitor for the preparation of a medicament formulated for topical application for the prophylaxis and/or treatment of breast cancer, where the medicament contains no antigestagens.
2. Use according to claim 1, characterized in that the medicament contains formestane (4-hydroxyandrost-4-ene-3,17-dione) and/or a pharmacologically active formestane derivative.
3. Use according to claim 2, characterized in that the medicament contains 4-O-acetylandrost-4-ene-3,17-dione.
4. Use according to one of claims 1 to 3, characterized in that the medicament additionally contains substances for promoting skin penetration.
5. Use according to claim 4, characterized in that the medicament contains DMSO.
6. Use according to one of claims 1 to 5, characterized in that the medicament is formulated as an ointment, cream, gel, emulsion or lotion.
7. Use according to claim 6, characterized in that the active compound content is 0.0001-20% by weight, preferably 0.6-10% by weight, further preferably 1-5% by weight.
US10/016,107 1998-03-18 2001-12-17 Medicament for preventing and/or treating a mammary carcinoma, containing a steroidal aromatase inhibitor Abandoned US20020086856A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/016,107 US20020086856A1 (en) 1998-03-18 2001-12-17 Medicament for preventing and/or treating a mammary carcinoma, containing a steroidal aromatase inhibitor
US10/227,523 US20030092693A1 (en) 1998-03-18 2002-08-26 Medicament for preventing and/or treating a mammary carcinoma, containing a steroidal aromatase inhibitor
US11/315,003 US8343948B2 (en) 1998-03-18 2005-12-23 Medicament for preventing and/or treating mammary carcinoma, containing a steroidal aromatase inhibitor

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EPEP98104949.7 1998-03-18
EP98104949A EP0943333A1 (en) 1998-03-18 1998-03-18 Medicament for the prevention and/or treatment of breast cancer comprising an inhibitor of estrogen synthesis
US64635500A 2000-11-16 2000-11-16
US10/016,107 US20020086856A1 (en) 1998-03-18 2001-12-17 Medicament for preventing and/or treating a mammary carcinoma, containing a steroidal aromatase inhibitor

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
PCT/EP1999/001374 Division WO1999047143A1 (en) 1998-03-18 1999-03-03 Medicament for preventing and/or treating a mammary carcinoma, containing a steroidal aromatase inhibitor
US09646355 Division 2000-11-16
US64635500A Division 1998-03-18 2000-11-16

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/227,523 Continuation US20030092693A1 (en) 1998-03-18 2002-08-26 Medicament for preventing and/or treating a mammary carcinoma, containing a steroidal aromatase inhibitor

Publications (1)

Publication Number Publication Date
US20020086856A1 true US20020086856A1 (en) 2002-07-04

Family

ID=26149100

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/016,107 Abandoned US20020086856A1 (en) 1998-03-18 2001-12-17 Medicament for preventing and/or treating a mammary carcinoma, containing a steroidal aromatase inhibitor
US10/227,523 Abandoned US20030092693A1 (en) 1998-03-18 2002-08-26 Medicament for preventing and/or treating a mammary carcinoma, containing a steroidal aromatase inhibitor
US11/315,003 Expired - Fee Related US8343948B2 (en) 1998-03-18 2005-12-23 Medicament for preventing and/or treating mammary carcinoma, containing a steroidal aromatase inhibitor

Family Applications After (2)

Application Number Title Priority Date Filing Date
US10/227,523 Abandoned US20030092693A1 (en) 1998-03-18 2002-08-26 Medicament for preventing and/or treating a mammary carcinoma, containing a steroidal aromatase inhibitor
US11/315,003 Expired - Fee Related US8343948B2 (en) 1998-03-18 2005-12-23 Medicament for preventing and/or treating mammary carcinoma, containing a steroidal aromatase inhibitor

Country Status (1)

Country Link
US (3) US20020086856A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2649994B1 (en) * 2011-01-31 2017-08-30 LUCOLAS-M.D. Ltd. Combinations of aromatase inhibitors and antioxidants

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11850451B2 (en) 2011-01-31 2023-12-26 Lucolas-M.D. Ltd. Cosmetic compositions and methods for improving skin conditions
EP3666276A1 (en) * 2018-12-14 2020-06-17 dcic Biopharmaceutical Limited Medication against estrogen-receptor beta (erbeta) positive breast tumor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2558373B1 (en) 1984-01-20 1987-07-03 Mauvais Jarvis Pierre ANTI-ESTROGEN MEDICINAL PRODUCT BASED ON 4-HYDROXYTAMOXIFENE FOR PERCUTANEOUS ADMINISTRATION
EP0310542B1 (en) 1987-10-01 1994-06-08 Schering Aktiengesellschaft Antigestagenic and antioestrogenic compounds for the treatment of hormone-dependent tumours
DE4039559A1 (en) 1990-12-07 1992-06-11 Schering Ag FUNCTIONALIZED VINYLAZOLES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS CONTAINING THIS VINYLAZOLES AND THE USE THEREOF FOR THE PRODUCTION OF MEDICINAL PRODUCTS
GB9212833D0 (en) 1992-06-17 1992-07-29 Glaxo Group Ltd Chemical compounds
WO1996008231A1 (en) 1994-09-14 1996-03-21 Central Sheffield University Hospitals Nhs Trust Control of hair growth
JP2001500841A (en) * 1996-03-29 2001-01-23 エス ヴェー パテントフェアヴェアツングス ゲゼルシャフト ミット ベシュレンクテル ハフツンク Cosmetic and cosmetic compositions for tightening and smoothing the skin in the case of impaired subcutaneous connective adipose tissue, especially fatty edema

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2649994B1 (en) * 2011-01-31 2017-08-30 LUCOLAS-M.D. Ltd. Combinations of aromatase inhibitors and antioxidants
EP2648721B1 (en) * 2011-01-31 2018-09-19 LUCOLAS-M.D. Ltd. Combinations of aromatase inhibitors and antioxidants
US10835540B2 (en) 2011-01-31 2020-11-17 Lucolas-M.D. Ltd. Pharmaceutical use

Also Published As

Publication number Publication date
US20060178353A1 (en) 2006-08-10
US8343948B2 (en) 2013-01-01
US20030092693A1 (en) 2003-05-15

Similar Documents

Publication Publication Date Title
US6432940B1 (en) Uses for androst-5-ene-3β, 17β-diol
EP0680327B1 (en) Therapeutic uses and delivery systems of dehydroepiandrosterone
EP1382340A1 (en) Therapeutic uses of dehydroepiandrosterone for treating diminished libido and osteoporosis
KR101403893B1 (en) Novel uses for 4,17? -Dihydroxyandrost-4-en-3-one
AU751040B2 (en) Medicament for preventing and/or treating a mammary carcinoma, containing a steroidal aromatase inhibitor
US8343948B2 (en) Medicament for preventing and/or treating mammary carcinoma, containing a steroidal aromatase inhibitor
Mor et al. Cutaneous complications of hormonal replacement therapy
MXPA00009126A (en) Medicament for preventing and/or treating a mammary carcinoma, containing a steroidal aromatase inhibitor
Aksel Therapeutic approaches to androgen excess
AU2004200178A1 (en) Pharmaceutical Compositions and Uses for Androst-5-ene-3B,17B-diol

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: SAVETHERAPEUTICS, AG, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:WIELAND, DR. HEINRICH;REEL/FRAME:016598/0636

Effective date: 20050928

AS Assignment

Owner name: MEDICAL DISCOVERIES, INC., UTAH

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SAVETHERAPEUTICS, A.G.;REEL/FRAME:016622/0458

Effective date: 20050928